Vestal Point Capital reported a 5.4% stake in Enliven Therapeutics ELVN · 3,250,000 sh · amendment · passive holder

Trade details

Type: 5% stake report
Report: 13G passive · amendment
Stake: 5.4%
Last report: 6.5% · filed 26/02/17
Shares held: 3,250,000 sh
Class: Common Stock, par value $0.001 per share
Stock: Enliven Therapeutics ELVN
Holder: Vestal Point Capital
Event date: 26/03/31
Filed: 26/05/15

5.4% stake · −1.1pp from the last report

Stake: 5.4%
Last report: 6.5%
Since last report: −1.1pp

Enliven Therapeutics trades, last 26 weeks

What else happened in Enliven Therapeutics around then

Filed or reported within 30 days of the trade day · 03/01~04/30

Vestal Point Capital's other 5% stake reports

Vestal Point Capital
5% stakeMonte Rosa Therapeutics
5% stake
Monte Rosa Therapeutics
GLUE
5.4% stake
4,600,000 sh
5.4% stake
Filed 08/14
Vestal Point Capital
5% stakeMyriad Genetics
5% stake
Myriad Genetics
MYGN
6.1% stake
5,735,000 sh
6.1% stake
Filed 08/14
Vestal Point Capital
5% stakeSolid Biosciences
5% stake
Solid Biosciences
SLDB
4.8% stake
4,833,796 sh
4.8% stake
Filed 08/14
Vestal Point Capital
5% stakeImmunocore Holdings
5% stake
Immunocore Holdings
IMCR
3.5% stake
1,800,000 sh
3.5% stake
Filed 08/14
Vestal Point Capital
5% stakeNurix Therapeutics
5% stake
Nurix Therapeutics
NRIX
7.8% stake
8,050,000 sh
7.8% stake
Filed 08/14